Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$64.95 USD

64.95
82,928

-0.48 (-0.73%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $64.94 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ANIP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 221 53 100 8 62
Receivables 162 165 129 96 72
Notes Receivable 0 0 0 0 0
Inventories 111 105 82 61 48
Other Current Assets 25 20 11 6 5
Total Current Assets 520 344 322 170 188
Net Property & Equipment 45 43 53 41 41
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 91 81 68 52 38
Intangibles 237 280 322 192 184
Deposits & Other Assets 12 11 7 6 6
Total Assets 904 760 772 461 457
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 37 29 23 11 15
Current Portion Long-Term Debt 1 1 1 13 10
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 88 69 64 50 37
Income Taxes Payable 8 0 0 4 0
Other Current Liabilities 12 0 0 0 0
Total Current Liabilities 145 99 88 79 62
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 285 286 287 172 176
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 17 36 39 14 7
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 447 422 413 265 244
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 25 25 25 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 514 404 388 214 201
Retained Earnings -80 -97 -48 -5 18
Other Equity 9 12 -3 -11 -5
Treasury Stock 10 5 3 2 1
Total Shareholder's Equity 458 339 359 196 213
Total Liabilities & Shareholder's Equity 904 760 772 461 457
Total Common Equity 433 314 334 196 213
Shares Outstanding 20.40 17.50 16.90 12.30 12.10
Book Value Per Share 21.21 17.93 19.76 15.91 17.59

Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 221 193 162 68
Receivables NA 162 179 173 175
Notes Receivable NA 0 0 0 0
Inventories NA 111 107 104 104
Other Current Assets NA 25 19 20 19
Total Current Assets NA 520 497 459 365
Net Property & Equipment NA 45 44 44 43
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 91 84 82 81
Intangibles NA 237 248 259 267
Deposits & Other Assets NA 12 16 16 9
Total Assets NA 904 890 859 765
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 37 34 29 33
Current Portion Long-Term Debt NA 1 1 1 1
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 88 75 68 70
Income Taxes Payable NA 8 1 0 0
Other Current Liabilities NA 12 24 25 23
Total Current Liabilities NA 145 134 123 126
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 285 285 285 285
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 16 17 14
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 447 435 425 426
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 25 25 25 25
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 514 507 495 408
Retained Earnings NA -80 -81 -90 -96
Other Equity NA 9 14 14 11
Treasury Stock NA 10 10 9 9
Total Shareholder's Equity NA 458 455 434 339
Total Liabilities & Shareholder's Equity NA 904 890 859 765
Total Common Equity 0 433 430 410 315
Shares Outstanding 21.00 20.40 20.40 20.30 18.00
Book Value Per Share 0.00 21.21 21.07 20.18 17.48